AstraZeneca maintains an option for a global exclusive licence for the candidate products developed through the deal. Credit: Robert Way / Shutterstock.com. AstraZeneca has concluded an equity investment in clinical-stage biotechnology company Cellectis. The investment comes after the companies entered an equity investment and research partnership agreement in November 2023. The companies will focus on developing